Skip to main content
. Author manuscript; available in PMC: 2018 Dec 5.
Published in final edited form as: Pharmacogenet Genomics. 2011 Sep;21(9):539–551. doi: 10.1097/FPC.0b013e328348c76b

Table 2.

Kinetic analysis of OLZ glucuronidation in HLMs of varying UGT1A4 and UGT2B10 genotypes.

OLZ-10-N-glucuronide isomer 1 OLZ-10-N-glucuronide isomer 2 OLZ-4’-N-glucuronide

HLM genotype
Vmax
(pmol·min−1·mg−1)
KM
(µM)
Vmax/KM
(µl·min−1·mg−1)
Vmax
(pmol·min−1·mg−1)
KM
(µM)
Vmax/KM
(µl·min−1·mg−1)
Vmax
(pmol·min−1·mg−1)
KM
(µM)
Vmax/KM
(µl·min−1·mg−1)
UGT1A4(*1/*1)/
UGT2B10(*1/*1)*
94.0 ± 14 352 ± 59 0.28 ± 0.08 63 ± 23 311 ± 27 0.2 ± 0.07 82 ± 20 317 ± 39 0.26 ± 0.07
UGT1A4(*1/*3)/
UGT2B10(*1/*1)*
160 ± 14a 328 ± 33 0.50 ± 0.08b 73 ± 17 239 ± 22b 0.31 ± 0.08 70 ± 24d 263 ± 59 0.26 ± 0.04e
UGT1A4(*3/*3)/
UGT2B10(*1/*1)*
188 ± 47b 268 ± 41 0.70 ± 0.07c 106 ± 16 263 ± 86 0.42 ± 0.08 156 ± 18b 337 ± 37 0.46 ± 0.01c
UGT2B10(*1/*2)/
UGT1A4(*1/*1)**
56 ± 23d 302 ± 50 0.19 ± 0.08f 30 ± 14e 196 ± 54b 0.16 ± 0.09 47 ± 20e 602 ± 57a,e 0.08 ± 0.03b,g
UGT2B10(*2/*2)/
UGT1A4(*1/*1)**
69 273 0.25 41.5 271 0.15 37 796 0.047
*

Three HLM with the UGT1A4 (*1/*1) genotype, three HLM with the UGT1A4 (*1/*3) genotype, and two HLM with the UGT1A4 (*3/*3) genotype were examined in this analysis. Only HLM with the UGT2B10 (*1/*1) genotype was used to compare varying UGT1A4 genotypes. HLMs of each genotype were chosen at random.

**

Three HLM with the UGT2B10 (*1/*2) genotype and the single HLM with the UGT2B10 (*2/*2) genotype were examined in this analysis. Only HLM with the UGT1A4 (*1/*1) genotype were used to compare varying UGT2B10 genotypes.

a

p<0.005

b

p<0.05

c

p<0.01 versus the corresponding value for HLM with the UGT1A4 (*1/*1)/UGT2B10 (*1/*1) genotype.

d

p<0.05

e

p<0.01

f

p<0.005

g

p<1 versus the corresponding value for HLM with the UGT1A4 (*3/*3)/UGT2B10 (*1/*1) genotype.